2018
DOI: 10.1016/j.jval.2018.04.029
|View full text |Cite
|
Sign up to set email alerts
|

Similarities and Differences in European HTA Evidence Requirements: One for All or One for None?

Abstract: S7of pembrolizumab in kr is 1M, 1.3M, 999K, 795K, and 816K, respectively. Among all the indicated population, the weighted cost per QALY was kr 1M/QALY. The results of sensitivity analyses for other key model parameters were robust. ConCluSionS: A holistic cost-effectiveness model of multi-indication drugs provides HTA bodies a useful tool to evaluate the overarching value of anti-cancer drugs and to alleviate the burden of repetitive appraisals in the era of targeted therapies. Analyses show the cost-effectiv… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles